trending Market Intelligence /marketintelligence/en/news-insights/trending/X0NIFGmnZlcqoDGmAl_37A2 content esgSubNav
In This List

Henry Schein names board for animal health spinoff Covetrus


Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection


Japan M&A By the Numbers: Q4 2023


Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity

Henry Schein names board for animal health spinoff Covetrus

Henry Schein Inc. has designated members to the board for new animal care spinoff Covetrus.

The new spinoff has been formed through a joint venture between Henry Schein's animal health business and a merger with privately held Vets First Choice. Covetrus will focus on the companion, equine and large-animal veterinary markets.

Henry Schein in a Jan. 14 press release announced the newly formed board, which will include Vets First Choice Chairman David Shaw as chairman and former Ernst & Young Chairman and CEO Philip Laskawy as lead independent director.

Also added to the board will be:

• Benjamin Shaw, CEO of Covetrus and Vets First Choice.

• Betsy Atkins, CEO of venture capital firm Baja LLC.

• Deborah Ellinger, former private equity executive and currently with The Boston Consulting Group.

• Sandra Helton, former CFO of Telephone and Data Systems Inc.

• Mark Manoff, former partner and Americas Vice Chair of Ernst & Young.

• Edward McNamara, president and co-founder of venture-building firm TeamLaunch LLC.

• Steven Paladino, Henry Schein CFO and board member.

• Ravi Sachdev, partner at Clayton Dubilier & Rice.

• Benjamin Wolin, former CEO of Everyday Health and advisor for 3L Capital.